Glucagon Like Peptide 1 Based Therapies: A New Horizon in Obesity Management The Dangers of BPC 157: FDA Warnings and Online Sales BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Comparing the Big 3, Semaglutide, Tirzepatide and Retatrutide : r Mounjaro This is one of the biggest peptide regulatory shifts in years. And it's just getting started. The FDA has taken its first step toward reversing its 2023 stance, removing 12 peptides from